Drug - Ventavis (inhaled iloprost), Tyvaso (inhaled treprostinil)
April 2010
Therapeutic area - Pulmonary arterial hypertension
Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms.
It must be inhaled via INEB® AAD® (Adaptive Aerosol Delivery) System.
Payment for Ventavis (ilorprost) will be authorized if:
Payment for Tyvaso (treprostinil) will be authorized if:
The State will authorize payment of the first fill only.
Pharmacy documentation of benefit and tolerability is required for subsequent fills.
After patient has demonstrated benefit and tolerability for 2 consecutive months, then 30 day supplies are allowed and PA extension up to 6 months.
Tyvaso is supplied as 2.9 mL ampules, which contain 4 doses. The AWP of each mL is $165.27. The AWP for 2.9mL (one day) is $480, and state cost ~$408. The cost to the state (after discounts and rebates) for a month of therapy is $10,466. This is a little more than twice the cost of Ventavis if Ventavis is dosed 6 times per day. It is about 30% more than Ventavis if Ventavis is dosed 9 times per day.
MHCP Provider Call Center 651-431-2700 or 800-366-5411